e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Genetics and genomics of lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Methylation of p16 in EBUS-TBNA samples as a predictor of advanced disease in lung cancer
L. Millares, L. Setó, F. Andreo, J. Sanz, M. Serra, C. Monton, E. Monsó (Sabadell, Mallorca, Badalona, Spain)
Source:
Annual Congress 2013 –Genetics and genomics of lung disease
Session:
Genetics and genomics of lung disease
Session type:
Thematic Poster Session
Number:
1407
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Millares, L. Setó, F. Andreo, J. Sanz, M. Serra, C. Monton, E. Monsó (Sabadell, Mallorca, Badalona, Spain). Methylation of p16 in EBUS-TBNA samples as a predictor of advanced disease in lung cancer. Eur Respir J 2013; 42: Suppl. 57, 1407
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Assessment of
SHOX2
methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging
Source: Annual Congress 2013 –New frontiers for EBUS-TBNA: the mediastinum and beyond
Year: 2013
Dividing EBUS-TBNA samples for simultaneous histopathological and molecular analyses in lung cancer patients
Source: International Congress 2015 – Endoscopic ultrasound: an essential tool for interventional pulmonology
Year: 2015
Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Prevalence of preinvasive bronchial lesions in patients with lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS
Source: International Congress 2016 – Endosonography: EBUS/EUS (B)
Year: 2016
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Variation in lung cancer diagnosis in England
Source: Annual Congress 2013 –Quality management in thoracic oncology
Year: 2013
Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Epigenetic alterations in the circulating DNA from blood of patients with COPD and lung cancer
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Bronchoscopic semantics and diagnosis of lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
The risk of recurrence after intraoperative needle biopsy(INB) for preoperative undiagnosed early stage lung cancers
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Feasibility of OSNA in EBUS-TBNA of lung cancer patients
Source: International Congress 2014 – EBUS-TBNA: beyond the tracheobronchial wall
Year: 2014
Determinants of negative predictive value during EBUS-TBNA in diagnosis/staging of lung cancer
Source: International Congress 2015 – Developments in lung cancer diagnosis
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept